Citadel Advisors
COGT icon

Citadel Advisors’s Cogent Biosciences COGT Stock Holding History

Citadel Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.91M Sell
75,200
-15,700
-17% -$549K ﹤0.01% 5757
2026
Q1 		$3.5M Buy
90,900
+11,600
+15% +$428K ﹤0.01% 4962
2025
Q4 		$2.82M Buy
79,300
+57,300
+260% +$1.61M ﹤0.01% 5288
2025
Q3 		$316K Sell
22,000
-30,400
-58% -$360K ﹤0.01% 10240
2025
Q2 		$376K Buy
52,400
+32,600
+165% +$181K ﹤0.01% 9290
2025
Q1 		$119K Sell
19,800
-1,300
-6% -$10.2K ﹤0.01% 11219
2024
Q4 		$165K Sell
21,100
-3,800
-15% -$37.9K ﹤0.01% 10746
2024
Q3 		$269K Sell
24,900
-7,500
-23% -$73K ﹤0.01% 9551
2024
Q2 		$273K Buy
32,400
+16,300
+101% +$124K ﹤0.01% 9319
2024
Q1 		$108K Buy
16,100
+12,000
+293% +$74.2K ﹤0.01% 11246
2023
Q4 		$24.1K Sell
4,100
-900
-18% -$6.9K ﹤0.01% 12465
2023
Q3 		$48.8K Buy
5,000
+4,100
+456% +$48.6K ﹤0.01% 11784
2023
Q2 		$10.7K Sell
900
-3,300
-79% -$37.9K ﹤0.01% 13189
2023
Q1 		$45.3K Buy
4,200
+3,000
+250% +$38.4K ﹤0.01% 12290
2022
Q4 		$13.9K Sell
1,200
-18,900
-94% -$234K ﹤0.01% 13418
2022
Q3 		$300K Sell
20,100
-100
-0.5% -$1.37K ﹤0.01% 9583
2022
Q2 		$182K Buy
+20,200
New +$138K ﹤0.01% 10803

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Citadel Advisors's COGT Position: Q2 2026 in Review

Citadel Advisors reduced its Cogent Biosciences (COGT) stake by 50% in Q2 2026, selling an estimated $30.3M and leaving 849,694 shares worth $32.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1992.

Citadel Advisors first reported a position in COGT in Q1 2018 and has held it in 27 quarters since. The position peaked at $66M in Q1 2026. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Citadel Advisors held 849,694 shares of Cogent Biosciences worth $32.9M as of Q2 2026.
  • Citadel Advisors sold 865,233 Cogent Biosciences shares in Q2 2026, an estimated $30.3M.
  • Cogent Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #1992 holding.
  • Citadel Advisors first reported a position in Cogent Biosciences in Q1 2018 and has held it in 27 quarters since.
  • Citadel Advisors's Cogent Biosciences position peaked at $66M in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.